|
|
|
|
Kyverna Therapeutics Inc (NASDAQ: KYTX) |
|
|
|
| |
Kyverna Therapeutics Inc 's Quick Ratio
KYTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Regardless of the sequential decrease in Current Liabilities, during the first quarter 2025, Quick Ratio deteriorated to 7.29 a new company low.
Within Biotechnology & Pharmaceuticals industry 33 other companies have achieved higher Quick Ratio than Kyverna Therapeutics Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 334, from total ranking in the fourth quarter 2024 at 344.
Explain Quick Ratio?
How much Cash & cash equivalents KYTX´s has?
What are KYTX´s Current Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| KYTX Quick Ratio |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Current Liabilities Change |
52.26 % |
- |
- |
- |
- |
| Y / Y Cash & cash equivalent Change |
-34.38 % |
- |
- |
- |
- |
| Quick Ratio MRQ |
7.29 |
8.47 |
10.38 |
14.75 |
16.91 |
| KYTX's Total
Ranking |
# 334 |
# 344 |
# 267 |
# 198 |
# 0 |
| Seq. Current Liabilities Change |
-1.37 % |
8.94 % |
31.97 % |
7.38 % |
- |
| Seq. Cash & cash equivalent Change |
-15.15 % |
-11.07 % |
-7.12 % |
-6.37 % |
- |
| Quick Ratio first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 34 |
| Healthcare Sector |
# 184 |
| Overall Market |
# 334 |
| Quick Ratio Statistics |
| High |
Average |
Low |
| 16.91 |
11.56 |
7.29 |
| (Mar 31 2024) |
|
(Mar 31 2025) |
Cumulative Kyverna Therapeutics Inc 's Quick Ratio
KYTX's Quick Ratio for the trailling 12 Months
KYTX Quick Ratio |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Current Liabilities TTM Growth |
455.73 % |
- |
- |
- |
- |
| Y / Y Cash & cash equivalent TTM Growth |
223.55 % |
- |
- |
- |
- |
| Quick Ratio TTM |
9.85 |
12.02 |
13.59 |
15.79 |
16.91 |
| Total Ranking TTM |
# 2317
| # 2820
| # 129
| # 86
| # 0
|
| Seq. Current Liabilities TTM Growth |
10.38 % |
44.22 % |
68.33 % |
107.38 % |
- |
| Seq. Cash & cash equivalent TTM Growth |
-9.61 % |
27.56 % |
44.91 % |
93.63 % |
- |
On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2025 to $33.29 millions, cumulative Quick Ratio decreased to 9.85 below the Kyverna Therapeutics Inc average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Biotechnology & Pharmaceuticals industry 118 other companies have achieved higher Quick Ratio than Kyverna Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2317, from total ranking during the twelve months ending fourth quarter 2024 at 2820.
Explain Quick Ratio?
How much Cash & cash equivalents KYTX´s has?
What are KYTX´s Current Liabilities?
| TTM Quick Ratio Company Ranking |
| Within: |
No. |
| Within the Biotechnology & Pharmaceuticals Industry |
# 119 |
| Healthcare Sector |
# 683 |
| Within the Market |
# 2317 |
| trailing twelve months Quick Ratio Statistics |
| High |
Average |
Low |
| 12.02 |
10.93 |
9.85 |
| (Dec 31 2024) |
|
(Mar 31 2025) |
|
Date modified: 2025-05-15T04:35:49+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
